Pre-operative assessment of axillary lymph node status in patients with breast adenocarcinoma using intravenous 99mtechnetium mAb-170H.82 (Tru-Scint(®)AD®)

Breast Cancer Research and Treatment

Volumn 45, Issue 1, 1997, Pages 29-37

  Dessureault, Sophie ^a   Koven, Irv ^a   Reilly, Raymond M ^b   Couture, Jean ^a   Schmocker, Beverly ^a   Damani, Manzur ^a   Kirsh, Joel ^a   Ichise, Masanori ^a   Sidlofsky, Saul ^a   McEwan, Alexander J B ^c,d   Boniface, Graeme ^d   Stern, Hartley ^a   Gallinger, Steven ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

^d Biomira Inc   (Canada)

Author keywords

99mTc mAB 170h.82; Axillary imaging; Breast adenocarcinoma; Immunoscintigrapy; Tru Scint AD(T)M

Indexed keywords

ANTIBODY CONJUGATE; MONOCLONAL ANTIBODY; TECHNETIUM 99M;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST ADENOCARCINOMA; CANCER SCINTISCANNING; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; IMMUNOSCINTIGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYMPH NODES; MIDDLE AGED; NEOPLASM STAGING; ORGANOTECHNETIUM COMPOUNDS; PROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 8544232152     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005878113826     Document Type: Article

References (29)

1. Henderson IC, Canellos GP: Cancer of the breast: the past decade (first of two parts). N Engl J Med 302: 17-30, 1980
2. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL: Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 222: 394-401, 1995
3. Uren RF, Howman-Giles RB, Thompson JF, Malouf D, Ramsey-Stewart G, Niesche FW, Renwick SB: Mammary lymphoscintigraphy in breast cancer. J Nucl Med 36: 1775-1780, 1995
4. Allan SM: The prospects for imaging lymph nodes in breast cancer. Eur J Nucl Med 19: 836-837, 1992
5. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL: Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 187: 743-750, 1993
6. Tse NY, Hoh CK, Hawkins RA, Zinner MJ, Dahlbom M, Choi Y, Maddahi J, Brunicardi FC, Phelps ME, Glaspy JA: The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 216: 27-34, 1992
7. McLean RG, Ege GN: Prognostic value of axillary lymphoscintigraphy in breast carcinoma patients. J Nucl Med 27: 1116-1124, 1986
8. Schatten C, Pateísky N, Enzelsberger H, Grouix B, Mandeville R: Clinical value of immunolymphoseintigraphy in patients with breast cancer. In Vivo 2: 321-324, 1988
9. Tjandra JJ, Sacks NP, Thompson CH, Leyden MJ, Stacker SA, Lichtenstein M, Russell IS, Collins JP, Andrews JT, Pieters GA et al.: The detection of axillary lymph node metastases from breast cancer by radiolabelled monoclonal antibodies: a prospective study. Br J Cancer 59: 296-302, 1989
10. Larson SM: Clinical radioimmunodetection, 1978-1988: overview and suggestions for standardization of clinical trials. Cancer Res 50: 892s-898s, 1990
11. Rhodes HA, Zamora PO, Newell KD, Valdez EF: Technetium-99m labelling of murine monoclonal antibody fragments. J Nucl Med 27: 685-693, 1986
12. Schwarz A, Steinstrasser A: A novel approach to the Tc-99m-labelled monoclonal antibodies. J Nucl Med 28: 721, 1987
13. Fritzberg AR: Advances in 99mTc-labeling of antibodies. Nuklearmedizin 26: 7-12, 1987
14. Fritzberg AR, Abrams PG, Beaumier PL, Kasina S, Morgan AC, Rao TN, Reno JM, Sanderson JA, Srinivasan A, Wilbur DS et al.: Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent. Proc Natl Acad Sci USA 85: 4025-4029, 1988
15. Fritzberg AR, Berninger RW, Hadley SW, Wester DW: Approaches to radiolabeling of antibodies for diagnosis and therapy of cancer. Pharmac Res 5: 325-334, 1988
16. Baum RP, Hertel A, Lorenz M, Schwarz A, Encke A, Hor G: 99mTc-labelled anti-CEA monoclonal antibody for tumour immunoscintigraphy: first clinical results. Nucl Med Commun 10: 345-352, 1989
17. Muxi A, Sola M, Bassa P, Pons F, Garcia A, Moragas M, Lo- mena F, Herranz R, Fernandez R, Trias M et al.: Radioimmunoscintigraphy of colorectal carcinoma with a 99mTc-labelled anti-CEA monoclonal antibody (BW 431/26), Nucl Med Commun 13: 261-270, 1992
18. Longenecker BM, Willans DJ, MacLean CD, Selvaraj S, Suresh MR, Noujaim AA: Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers. J Natl Cancer Inst 78: 489-496, 1987
19. McEwan AJ, MacLean GD, Hooper HR, Sykes T, McOuarrie SA, Golberg L, Bodnar DM, Lloyd SL, Noujaim AA: mAb 170H.82: an evaluation of a novel panadenocarcinoma monoclonal antibody labelled with 99mTc and with 111In. Nucl Med Commun 13: 11-19, 1992
20. McEwan AJB, MacLean GD, Golberg L, Boniface GR, Sykes T, McQuarrie SA, Amyotte G, Noujaim AA: Tc-99m 170H.82 (Tru-Scint®AD™): a new monoclonal antibody for imaging breast cancer - a preliminary analysis [abstract]. J Nucl Med 34: 213P, 1993
21. Kairemo KJ: Immunolymphoscintigraphy with 99mTc-labelled monoclonal antibody (BW 431/26) reacting with carcinoembryonic antigen in breast cancer. Cancer Res 50: 949s-954s, 1990
22. Lind P, Smola MG, Lechner P, Ratschek M, Klima G, Koltringer P, Steindorfer P, Eber O: The imunoscintigraphic use of Tc-99m-labelled monoclonal anti-CEA antibodies (BW 431/26) in patients with suspected primary, recurrent and metastatic breast cancer. Int J Cancer 47: 865-869, 1991
23. Goldenberg DM, Goldenberg H, Sharkey RM, Higginbotham-Ford E, Lee RE, Swayne LC, Burger KA, Tsai D, Horo- witz J, Hall TC, Pinsky CM, Hansen HJ: Clinical studies of cancer radioimmunodetection with carcinoembryonic antigen monoclonal antibody fragments labeled with 1231 or 99mTc. Cancer Res Suppl 50: 909s-921s, 1990
24. Brown BA, Dearborn CB, Drozynski CA, Sands H: Pharmacokinetics of 99mTc-metallothionein-B72.3 and its F(ab')2 fragment. Cancer Res Suppl 50: 835s-839s, 1990
25. Lamki LM, Buzdar AU, Singletary SE, Rosenblum MG, Bhadkamkar V, Esparza L, Podoloff DA, Zukiwski A, Hortobagyi GN, Murray JL: Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study. J Nucl Med 32: 1326-1332, 1991
26. Taylor JL, Taylor DN, Lowry C, Keeling AA, Bradwell AR, McIntosh A, Rhodes A: Radioimmunoscintigraphy of metastatic breast carcinoma. Eur J Surg Onc 18: 57-63, 1992
27. Schatten C, Barrada M, Mandeville R, Enzelsberger H, Angelberger P, Czerwenka K, Kubista E, Pateisky N: Combined use of 1231-labelled BCD-F9 and 4C4 monoclonal antibody with dissimilar specificity for breast cancer: implication for the detection limit of immunolymphoscintigraphy in the assessment of axillary lymph node metastases. Nucl Med Commun 15: 422-429, 1994
28. Pateisky N, Schatten C, Enzelsberger H, Czerwenka K, Burchell J, Mandeville R: Immunlymphszintigraphie. Dtsch Med Wschr 113: 250-255, 1988
29. Rockoff SD, Goodenough DS, McIntire KR: Theoretical limitations in the immunodiagnostic imaging of cancer with computer tomography and nuclear scanning. Cancer Res 40: 3054-3058, 1980